Please login to the form below

Not currently logged in
Email:
Password:

Histogenics names former MedImmune president as CEO

Peter Greenleaf to lead regenerative medicine company

Peter Greenleaf, HistogenicsPeter Greenleaf, the former president of AstraZeneca's (AZ) biologics arms MedImmune, has joined regenerative medicine company Histogenics as CEO.

Greenleaf was appointed president of MedImmune and related investment business MedImmune Ventures in February 2010, but three years later, he was one of several casualties in a shake-up of AZ's research efforts that also included the departure of president of R&D Martin Mackay.

Prior to serving as president, Greenleaf led the development of the MedImmune's global marketing and portfolio organisations and managed the broader commercial, corporate development and strategy functions.

Outside MedImmune, he has held several key leadership roles at Centocor, including VP of the US gastroenterology commercial group, as well as roles at Hallmark Cards, Boehringer Mannheim and US Healthcare.

In his new role, he will lead a company that specialises in combining cell therapy and tissue engineering technologies to develop products primarily for orthopaedic tissue repair.

This includes lead candidate NeoCart – a cartilage tissue implant in phase III trials.

“Peter's expertise in growing smaller biotech companies into industry leaders will be critical as we work to move NeoCart through pivotal trials and ultimately toward launch and commercialisation,” said Histogenics chairman Garheng Kong.

“While NeoCart will be the main focus in the near term, Peter will also help facilitate our vision for building out the company's platform technology and the future growth plans for the organisation.”

12th June 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics